Pre-market hot trades in US stocks: XCF Global up 16.60% in pre-market; TruGolf down 11.63% in pre-market

Pre-market Hot Trades in US Stocks

XCF Global is up 16.60% in pre-market trading. Based on recent key news:

1. On November 17, XCF Global signed a memorandum of understanding with BGN to promote the global expansion of sustainable aviation fuel. This collaboration will accelerate the aviation industry's transition to net-zero emissions, boost market confidence, and lead to a rise in stock prices.

2. On November 18, BGN issued a statement clarifying the details of its cooperation with XCF Global, eliminating market misunderstandings and further driving up stock prices.

3. On November 17, XCF Global released a statement emphasizing its leading position in the sustainable aviation fuel sector and future development plans, enhancing investor confidence and driving up stock prices. The energy transition is accelerating, and the market is focused on sustainability.

TruGolf is down 11.63% in pre-market trading. Based on recent key news:

1. On November 17, TruGolf announced its Q3 2025 performance, showing strong profit margins and an enhanced balance sheet, with contract revenue growth supporting its long-term growth strategy. However, market concerns about its future profitability may lead to a decline in stock prices. Source: TruGolf Company Announcement

2. On November 17, TruGolf is advancing the development of E6 APEX, LaunchBox, and the TruGolf Range platform, which will debut at the 2026 PGA Show, while making progress in AI-driven analytics and "Golf Everywhere" franchise installations. Although these innovative projects showcase the company's future potential, they may not alleviate investor concerns in the short term. Source: Public Technologies

3. No other significant news recently. The market is skeptical about the short-term returns of innovative projects.

Top Gainers in Pre-market Trading of US Stocks

Olema Pharmaceuticals is up 238.03% in pre-market trading. Based on recent key news:

1. On November 18, Roche's breast cancer research made positive progress, and Olema Pharmaceuticals' main drug palazestrant is similar to Roche's drug, leading to significant stock price increases driven by market expectations for its clinical trial results. Olema Pharmaceuticals' stock rose 197.3% in pre-market trading, with a trading volume of 13.4 million shares, far exceeding the average daily trading volume over the past three months.

2. On November 17, analyst ratings showed Olema Pharmaceuticals as "Moderate Buy," but it was not included in the top recommended stocks list. Nevertheless, market attention to its potential continues to drive up stock prices. The biopharmaceutical industry has performed strongly recently, with noticeable capital inflows Can-Fite BioPharma pre-market rose 56.69%. Based on recent key news:

3. On November 18, Can-Fite BioPharma announced significant progress in its leading drug candidates for the treatment of cancer, liver disease, and inflammatory diseases. The company is in advanced clinical stages, targeting a market size of several billion dollars. This news drove the stock price significantly higher.

4. On November 18, Can-Fite BioPharma's drugs demonstrated excellent safety in clinical studies, further boosting investor confidence. The company's main drugs include Namodenoson and Piclidenoson for hepatocellular carcinoma and psoriasis.

5. On November 18, technical sentiment signals indicated a sell, but the market remains optimistic about Can-Fite BioPharma's potential, leading to a significant pre-market rise in stock price. The biopharmaceutical industry has been active recently, with investors focusing on new drug development progress.

Lobo Tech, pre-market rose 20.87%, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation